Olanzapine-LAI Summary

There are vast quality evidence-based researches that have been conducted addressing the use of LAI in patients with schizophrenia. There are definitely ups and downs, as well as different variables noted in every research; nonetheless, there have been some consistencies noted in the result of most studies. For instance, in the randomized double-blind study conducted by (Ascher-Svanum et al., 2013), it was conducted so to identify the factors that cause psychiatric hospitalization in patients during maintenance treatment with olanzapine-LAI (Ascher-Svanum et al., 2013). The study compared the safety and effectiveness of Olanzapine-LAI. In the study the patients started their treatment with oral Olanzapine that was slowly tapered down: 405mg/4weeks, 300mg/2weeks, and 150mg/2weeks in addition to receiving sub therapeutic Olanzapine-LAI (45 mg/4 weeks) during the 6-months maintenance treatment of schizophrenic patients that were clinically stable (n=1064) (Ascher-Svanum et al., 2013).
This was …show more content…
For all result analysis, researcher used SAS software (Version 9.1, SAS Institute Inc., Cary, NC, USA) was used for all analyses (Crivera et al., 2011). The study included patients that 18-years or older (Crivera et al., 2011). These patients have to have a diagnosis of schizophrenia according to (DSM-IV), and are appropriate for the initiation of RLAT (Crivera et al., 2011). In addition, this population is at impending risk of injuring themselves or others or causing significant damage to property (Crivera et al., 2011). Further, patients that have hypersensitive to RLAT or any of its components, or who had been treated with investigational agents within the previous 30 days were not eligible for enrollment (Crivera et al.,